Seroprevalence of SARS-CoV-2 antibodies in Seattle, Washington: October 2019-April 2020

PLoS One. 2021 May 27;16(5):e0252235. doi: 10.1371/journal.pone.0252235. eCollection 2021.

Abstract

Background: The first US case of SARS-CoV-2 infection was detected on January 20, 2020. However, some serology studies suggest SARS-CoV-2 may have been present in the United States prior to that, as early as December 2019. The extent of domestic COVID-19 detection prior to 2020 has not been well-characterized.

Objectives: To estimate the prevalence of SARS-CoV-2 antibody among healthcare users in the greater Seattle, Washington area from October 2019 through early April 2020.

Study design: We tested residual samples from 766 Seattle-area adults for SARS-CoV-2 antibodies utilizing an ELISA against prefusion-stabilized Spike (S) protein.

Results: No antibody-positive samples were found between October 2, 2019 and March 13, 2020. Prevalence rose to 1.2% in late March and early April 2020.

Conclusions: The absence of SARS-CoV-2 antibody-positive samples in October 2019 through mid-March, 2020, provides evidence against widespread circulation of COVID-19 among healthcare users in the Seattle area during that time. A small proportion of this metropolitan-area cohort had been infected with SARS-CoV-2 by spring of 2020.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Antibodies, Viral / blood*
  • COVID-19 Serological Testing*
  • COVID-19* / blood
  • COVID-19* / epidemiology
  • COVID-19* / transmission
  • Female
  • Humans
  • Male
  • Prevalence
  • SARS-CoV-2 / metabolism*
  • Seroepidemiologic Studies
  • Washington

Substances

  • Antibodies, Viral